FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Shah, A; Bloomquist, E; Tang, SH; Fu, WT; Bi, YW; Liu, Q; Yu, JY; Zhao, P; Palmby, TR; Goldberg, KB; Chang, CJG; Patel, P; Alebachew, E; Tilley, A; Pierce, WF; Ibrahim, A; Blumenthal, GM; Sridhara, R; Beaver, JA; Pazdur, R

Shah, A (reprint author), US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.

CLINICAL CANCER RESEARCH, 2018; 24 (13): 2999

Abstract

On March 13, 2017, the FDA approved ribociclib (KISQALI; Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索